NCT05651126View on ClinicalTrials.gov

Psilocybin in Adults With and Without Autism Spectrum Disorder

NACompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

December 12, 2022

Primary Completion Date

August 23, 2024

Study Completion Date

August 23, 2024

Conditions
Autism Spectrum Disorder
Interventions
DRUG

Psilocybin 5 mg

Partial Serotonin (5HT) 1A/2A Receptor Agonist Psilocybin

DRUG

Psilocybin 2 mg

Partial Serotonin (5HT) 1A/2A Receptor Agonist Psilocybin

DRUG

Placebo

Inactive placebo

Trial Locations (1)

SE5 8AF

King's College London, London

All Listed Sponsors
collaborator

University of Cambridge

OTHER

lead

King's College London

OTHER